Viraday - Tenofovir Disoproxil Fumarate, Emtricitabine, and Efavirenz Tabs

Viraday combines three antiretroviral agents from two different drug classes into one tablet, simplifying HIV treatment for many patients. Tenofovir and Emtricitabine are nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs), while Efavirenz is a non-nucleoside reverse transcriptase inhibitor (NNRTI); together they work at different stages of the viral replication process to more effectively suppress HIV-1. This combination approach helps reduce viral load, allowing the immune system to recover and CD4 cell counts to improve over time. Being a single-tablet, once-daily regimen, Viraday can make it easier for patients to stay consistent with their treatment schedule, which is important for long-term viral suppression. It is typically taken on an empty stomach, often at bedtime, to help minimize certain side effects associated with Efavirenz. Regular follow-up with a healthcare provider is recommended to monitor viral load, CD4 counts, and overall organ function during treatment. Many patients using Viraday achieve durable viral suppression and meaningful improvements in immune health with consistent adherence. As with all antiretroviral therapy, it should be used under the guidance of an experienced healthcare provider as part of a comprehensive HIV care plan.